Skin Cancer

The FDA has granted a priority review to the MEK inhibitor cobimetinib for use in combination with the BRAF inhibitor Zelboraf to treat patients with BRAF V600–positive advanced melanoma.

Richard Joseph, assistant professor of medical oncology at Mayo Clinic in Jacksonville, Florida, explains how treatment outcomes for metastatic melanoma have grown in the past few years.

Omid Hamid, chief of clinical research and immunotherapy at The Angeles Clinic and Research Institute, explains how he helps ease his patients' fears after a diagnosis of metastatic melanoma.

Melanoma rates are on the rise, and is the most common form of cancer for young adults aged 25 to 29 years old.

Enormous medical gains have been made against melanoma over the past four years, and more are waiting in the wings.

At least 10 vaccine candidates have entered advanced testing phases on the strength of impressive early stage results.

Melanoma specialist, Suzanne L. Topalian discusses how new approved drugs and those in the pipeline for advanced melanoma are making an impact for patient.

In the past four months, the PD-1 inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) have been approved for the treatment of advanced melanoma. Jeffery S. Weber, a senior member at Moffitt Cancer Center in Tampa, Fla., provides insight on what this means for treating patients.

The Food and Drug Administration's calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

The PD-1 inhibitor Opdivo (nivolumab) was granted accelerated approval for patients with unresectable or metastatic melanoma following treatment with Yervoy (ipilimumab) or a BRAF inhibitor.

The annual meeting of the European Society for Medical Oncology (ESMO) was held in September to discuss the latest data on critical issues in cancer treatment, diagnostics, prevention, supportive care and more.

Several studies announcing the latest research in different cancers, including prostate, breast and lung cancers, were presented at the 2014 European Society of Medical Oncology's annual meeting in Madrid, Spain.

The latest in cancer prevention, diagnosis and treatment.

We know what we need to do to prevent skin cancer, and now is the time to do it.

Sun exposure during the earlier part of life, specifically in young white women, seems to be predictive of melanoma risk, according to a new study.

News on clinical trial results, drug approvals and updates on therapies.

The latest in cancer prevention, diagnosis & treatment.

Tafinlar and Mekinist target a specific tumor mutation in patients with metastatic or unresectable melanoma, a type of skin cancer.

Websites help consumers identify actinic keratosis.

Vaccines help the immune system uncover malignant cells.

Two new targeted therapies, which each focus on a different way to block cancer growth signaling, delayed disease progression in advanced melanoma patients.

Picato OK'ed to treat precancerous skin lesions.

The skin is vulnerable to several types of skin cancer.

Melanoma studies with Yervoy and vemurafenib show benefit in advanced disease.

New therapies are enhancing melanoma treatment.

Calming the effects of radiation on the skin.

Skin cancer advocates hope a new 10 percent tax on indoor tanning will pull tanners out from under the bulbs.

For metastatic melanoma patients who were out of treatment options, the immune system-targeted drug ipilimumab extended their lives by nearly four months compared with an investigational vaccine called gp100.

Updates from the annual meeting of the American Society of Clinical Oncology.

A new organization aims to strike back at melanoma by developing the first-ever international melanoma tissue bank.